Kulkarni Samarth 4

4 · CRISPR Therapeutics AG · Filed Mar 24, 2026

AI-generated summary of this filing

Updated Mar 24, 2026

CRISPR Therapeutics (CRSP) CEO Samarth Kulkarni Sells 10,020 Shares

What Happened

Samarth Kulkarni, CEO of CRISPR Therapeutics (CRSP), sold 10,020 common shares in an open-market transaction on 2026-03-23 at $46.78 per share, totaling $468,736.
The Form 4 also reports multiple March 20, 2026 derivative-related items: a stock option grant for 114,249 shares (derivative), an RSU award for 81,875 shares, and entries showing 19,687 shares marked as an exercise/conversion (reported both as acquired and disposed). The filing also references previously granted RSUs (78,750) with a vesting tranche on 2026-03-20.
The 10,020-share sale was reported as a withholding sale to satisfy tax obligations associated with RSU vesting (per the company’s RSU Settlement Policy), not a discretionary sell decision by the CEO.

Key Details

Transaction dates/prices: 2026-03-20 (option grant and RSU grants; exercise/conversion of 19,687 shares reported), 2026-03-23 sale at $46.78/share (10,020 shares; $468,736).
Shares owned after transaction: not specified in the filing.
Notable footnotes:
- F3: The 10,020-share sale was mandated to cover tax withholding on RSU vesting (company policy) — not discretionary.
- F4–F6: Describe vesting schedules — option (114,249 shares) vests monthly over 48 months starting Apr 20, 2026; RSU (81,875) vests in four annual tranches (Mar 20, 2027–2030); prior RSU (78,750 from 2024) vests quarterly through 2028.
- F1: Some shares remain subject to a lock-up with underwriters for the issuer’s convertible note offering.
Timeliness: Period of report is 2026-03-20 and the Form 4 was filed 2026-03-24; filing appears timely per Form 4 reporting rules.

Context

Derivative explanation: the "M" code indicates an option exercise/conversion. The filing shows 19,687 shares both acquired and disposed on the same date, which commonly reflects a net or cashless exercise (exercise and immediate sale/withholding), though the form does not state cash proceeds for that entry.
RSU withholding sales to cover taxes are routine and generally do not signal voluntary insider selling for investment reasons. Purchases or outright discretionary buys carry more weight as bullish signals; this filing mainly reflects compensation-related activity plus a required tax-withholding sale.

Form 4

Period: 2026-03-20

DirectorChief Executive Officer

Transactions

Exercise/Conversion
Common Shares
[F1][F2]
2026-03-20+19,687→ 265,521 total
Sale
Common Shares
[F3]
2026-03-23$46.78/sh−10,020$468,736→ 255,501 total
Award
Stock Option (Right to Buy)
[F1][F4]
2026-03-20+114,249→ 114,249 total
Exercise: $46.24Exp: 2036-03-20→ Common Shares (114,249 underlying)
Award
Restricted Stock Units
[F5][F1]
2026-03-20+81,875→ 81,875 total
→ Common Shares (81,875 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F1][F6]
2026-03-20−19,687→ 39,375 total
→ Common Shares (19,687 underlying)

Footnotes (6)

[F1]These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
[F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
[F3]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
[F4]This option was granted on March 20, 2026 with respect to 114,249 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.
[F5]This restricted stock unit award was granted on March 20, 2026 with respect to 81,875 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.
[F6]This restricted stock unit award was granted on March 20, 2024 with respect to 78,750 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

Signature

Elizabeth Ryland Waldinger, attorney-in-fact|2026-03-24

1 file